A medical drug devices for transdermal drug delivery systems (TDDS) comprising a novel iontophoretic polymeric microneedle device and its use in administration of drugs.

The present invention provides methods for determining whether a subject is allergic to an allergen, comprising administering to the subject's skin at an injection site a composition comprising the allergen, wherein the composition is administered with a microneedle delivery device; and monitoring the injection site of the subject's skin for the appearance of a hypersensitivity reaction, wherein the appearance of the hypersensitivity reaction indicates that the subject is allergic to the allergen.

The present invention provides a method for generating an immune response in a subject, comprising administering to the subject’s skin an immunizing composition comprising one or more cancer antigens, wherein the composition is administered with a microneedle delivery device.

Disclosed are devices for delivering a rheumatoid arthritis drug across a dermal barrier. The devices include microneedles for penetrating the stratum corneum and also include structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. The pattern of structures on the surface of the microneedles may include nano-sized structures.

A hybrid microneedle array and a method of fabricating the array is used for delivery of drugs, vaccines, and other therapeutic agents into tissues, including skin, heart, inner ear, and other tissues. The microneedle array can facilitate precise and reproducible intradermal delivery. Each microneedle has a dissolvable tip with a hollow body permitting the delivery of a variety of therapeutic agents into the skin. A fabrication process utilizes a two part mold to separately mold a dissolvable tip and a solid body portion of each microneedle in the array.

A drug administration device includes a substrate having a first surface, a projection extending from the first surface, and a solid drug. One direction that intersects with the first surface is a first direction, and one direction that extends along the first surface is a second direction. A groove serving as a receiving section is formed in the projection. The groove defines a cavity recessed in the first direction toward the substrate and extends in the second direction to open to a section of the peripheral surface of the projection. The drug is received in the groove.

An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e.g., a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device. The device may be rigid, or flexible, in which case a flexible device can be attached to a bio-degradable support scaffold that provides sufficient structural rigidity for insertion of the device into the target tissue. In certain “functionalized” embodiments of the invention, the CED device is equipped with integrated electrodes and/or a sensor (e.g., glutamate) to detect and convey selective parametric information. Another embodiment of the invention is directed to a CED method for drugs and/or other agents. The method may comprise the delivery of enzymes or other materials to modify tissue permeability and improve drug diffusion. Another embodiment of the invention is directed to a method for making a device for CED of drugs.

Disclosed is a drug compliance management method including a microneedle applicator configured to infuse a drug by means of a microneedle in the form of a wearable device, a patient terminal configured to process drug compliance information including drug infusion information received from the microneedle applicator and medication information separately input by a patient after administration, a server configured to transmit the drug compliance information received from the patient terminal, and an expert terminal configured to display drug compliance information collected from a plurality of patient terminals.

A microneedle including a projection having a through hole formed in the projection in a direction that the projection extends, and a tubular member having an end surface configured to support the projection when the end surface is pressed against a skin and a fluid is supplied through the through hole of the projection to the skin. The projection has a length H along the direction that the projection extends and the supporting surface has an area S such that a ratio of S/H is in a range of from 2.1 to 10.5.

The present disclosure relates to a medicament delivery device comprising at least one microneedle for delivering a medicament to a patient, and a system configured to enhance the penetration of the medicament into skin of the patient.